A cholesterol-lowering medication may expand its role in heart disease prevention, according to research showing it can reduce the risk of first-time heart attacks and strokes in high-risk patients with diabetes.
The drug, evolocumab, has traditionally been prescribed for people who already have cardiovascular disease. But new findings suggest it may benefit a broader population—specifically those at high risk who have not yet experienced a cardiac event or developed visible arterial blockages.
In trials involving high-risk diabetic patients, the medication demonstrated a 31% reduction in heart attack and stroke risk. The results suggest that starting treatment before plaque accumulation becomes detectable could prevent serious cardiac events.
Evolocumab works by lowering LDL cholesterol, the type associated with artery damage. By aggressively reducing cholesterol levels early, the drug may slow or prevent the underlying disease process that leads to heart attacks and strokes.
The findings could reshape how doctors approach prevention in vulnerable populations. Rather than waiting for signs of existing heart disease to appear, physicians might consider prescribing evolocumab to diabetic patients at high risk, potentially preventing cardiovascular problems before they develop.
The research represents a shift toward proactive treatment strategies. While the drug carries a cost consideration for healthcare systems and insurers, the potential to prevent first cardiac events in high-risk groups could offer significant public health benefits.
These results add to growing evidence that aggressive cholesterol management may be more important than previously thought in preventing heart disease, particularly for patients whose other risk factors—like diabetes—already put them at disadvantage.
Comments